Posted by Michael Wonder on 20 Feb 2021
Junshi Biosciences announces acceptance by the NMPA of supplemental new drug application for toripalimab combined with chemotherapy for the first-line treatment of nasopharyngeal carcinoma
19 February 2021 - Third sNDA for toripalimab in China.
Junshi Biosciences announced today that the National Medical Products Administration of China has accepted its supplemental new drug application for Toripalimab combined with chemotherapy for the first-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma.
